Published in J Am Chem Soc on February 09, 2005
New trends for metal complexes with anticancer activity. Curr Opin Chem Biol (2008) 2.06
Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today (2009) 1.47
Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase. J Biol Inorg Chem (2009) 1.26
Monofunctional and higher-valent platinum anticancer agents. Inorg Chem (2013) 1.13
Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des (2010) 1.13
Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano (2010) 1.12
Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev (2013) 1.11
Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev (2012) 1.06
Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes. Inorg Chem (2011) 1.02
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev (2016) 1.02
Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc (2014) 0.97
Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano (2013) 0.88
Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells. J Inorg Biochem (2012) 0.88
Encapsulation of Pt(IV) Prodrugs within a Pt(II) Cage for Drug Delivery. Chem Sci (2015) 0.84
Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance. ChemMedChem (2014) 0.82
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. Chem Commun (Camb) (2013) 0.81
Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem (2014) 0.80
Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity. Chem Biodivers (2012) 0.80
Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs. Chem Sci (2015) 0.78
Identification of the molecular mechanisms underlying the cytotoxic action of a potent platinum metallointercalator. J Chem Biol (2011) 0.77
Oxaliplatin analogues with carboxy derivatives of boldine with enhanced antioxidant activity. Bioinorg Chem Appl (2015) 0.75
The Platin-X series: activation, targeting, and delivery. Dalton Trans (2016) 0.75
Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position. Sci Rep (2016) 0.75
In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo. Invest New Drugs (2008) 0.75
Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin. Bioinorg Chem Appl (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med (2012) 1.78
Efficient dehydrogenation of formic acid using an iron catalyst. Science (2011) 1.71
Bioorganometallic chemistry--from teaching paradigms to medicinal applications. Chem Soc Rev (2008) 1.64
The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse. Am J Obstet Gynecol (2005) 1.43
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J Med Chem (2005) 1.35
Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation (2004) 1.31
From dysfunction to bis-function: on the design and applications of functionalised ionic liquids. Chemistry (2006) 1.31
Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity. Inorg Chem (2007) 1.30
Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med (2014) 1.27
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers (2008) 1.27
Ionic solid-state dimers and polymers derived from imidazolium dicarboxylic acids. Chemistry (2006) 1.22
Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials (2009) 1.19
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol (2008) 1.18
Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther (2006) 1.16
Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J (2012) 1.15
Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) (2013) 1.11
The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways. J Biol Inorg Chem (2008) 1.11
The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells. Angew Chem Int Ed Engl (2008) 1.10
Highly cytotoxic copper(II) complexes with modified paullone ligands. Inorg Chem (2010) 1.09
A gastrolith protein serving a dual role in the formation of an amorphous mineral containing extracellular matrix. Proc Natl Acad Sci U S A (2008) 1.09
Brønsted acidic ionic liquids and their zwitterions: synthesis, characterization and pKa determination. Chemistry (2004) 1.09
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol (2011) 1.08
An internal fluorescent probe based on anthracene to evaluate cation-anion interactions in imidazolium salts. Chemistry (2010) 1.07
Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. J Inorg Biochem (2007) 1.06
Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents. Dalton Trans (2010) 1.05
Revisiting the electronic structure of phosphazenes. Inorg Chem (2005) 1.05
Harmonic nanocrystals for biolabeling: a survey of optical properties and biocompatibility. ACS Nano (2012) 1.04
O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-β-D-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem (2012) 1.04
Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential. J Biol Inorg Chem (2012) 1.03
Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology (2015) 0.99
A well-defined iron catalyst for the reduction of bicarbonates and carbon dioxide to formates, alkyl formates, and formamides. Angew Chem Int Ed Engl (2010) 0.98
NMR, PGSE diffusion, and X-ray diffraction studies of lithium and potassium salts derived from diphenylphosphino(o-cyanophenyl)aniline and their crown ether complexes. Inorg Chem (2005) 0.97
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J Med Chem (2011) 0.97
A viable hydrogen-storage system based on selective formic acid decomposition with a ruthenium catalyst. Angew Chem Int Ed Engl (2008) 0.96
A protein involved in the assembly of an extracellular calcium storage matrix. J Biol Chem (2010) 0.96
Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem (2009) 0.96
Metal-based antitumour drugs in the post-genomic era: what comes next? Dalton Trans (2011) 0.95
transformation between diphosphinoamines and iminobiphosphines: a reversible P-N-P <--> N=P-P rearrangement triggered by protonation/deprotonation. Inorg Chem (2004) 0.95
Carbohydrate-metal complexes and their potential as anticancer agents. Curr Med Chem (2008) 0.95
Osmotic regulation of the Streptomyces lividans thiostrepton-inducible promoter, ptipA. Microbiology (2002) 0.95
Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach. Inorg Chem (2007) 0.95
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. J Med Chem (2008) 0.95
Synthesis, characterisation and biological properties of gold(III) compounds with modified bipyridine and bipyridylamine ligands. Dalton Trans (2010) 0.94
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem (2010) 0.93
Selective formic acid decomposition for high-pressure hydrogen generation: a mechanistic study. Chemistry (2009) 0.93
A cytotoxic ruthenium tris(bipyridyl) complex that accumulates at plasma membranes. Chembiochem (2009) 0.92
Transposon Express, a software application to report the identity of insertions obtained by comprehensive transposon mutagenesis of sequenced genomes: analysis of the preference for in vitro Tn5 transposition into GC-rich DNA. Nucleic Acids Res (2004) 0.92
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. Chemistry (2011) 0.92
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. Metallomics (2011) 0.91
Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin. Rapid Commun Mass Spectrom (2002) 0.91
Male-like behavioral patterns and physiological alterations induced by androgenic gland implantation in female crayfish. J Exp Biol (2003) 0.91
Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interactions with astrocytes and IL-6 release. Glia (2002) 0.91
Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties. J Med Chem (2010) 0.90
Dielectric response of imidazolium-based room-temperature ionic liquids. J Phys Chem B (2006) 0.90
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem (2005) 0.90
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials (2011) 0.90
CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J Inorg Biochem (2007) 0.89
Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells. Nanomedicine (Lond) (2012) 0.89
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) (2006) 0.89
Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem (2011) 0.89
Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J Med Chem (2005) 0.89
Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J Biol Inorg Chem (2009) 0.88
Evidence for drug release from a metalla-cage delivery vector following cellular internalisation. Chemistry (2010) 0.88
A mass spectrometric and molecular modelling study of cisplatin binding to transferrin. Chembiochem (2005) 0.88
Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. J Med Chem (2012) 0.87
Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg Chem (2006) 0.87
A supercooled imidazolium iodide ionic liquid as a low-viscosity electrolyte for dye-sensitized solar cells. Inorg Chem (2006) 0.87
Expression of an Androgenic Gland-Specific Insulin-Like Peptide during the Course of Prawn Sexual and Morphotypic Differentiation. ISRN Endocrinol (2011) 0.87
Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance. Mol Pharm (2011) 0.86
The dielectric response of room-temperature ionic liquids: effect of cation variation. J Phys Chem B (2007) 0.86
A facile approach for controlling the orientation of one-dimensional mesochannels in mesoporous titania films. J Am Chem Soc (2012) 0.86
Rational design of an organometallic glutathione transferase inhibitor. Angew Chem Int Ed Engl (2009) 0.86
Ruthenium porphyrin compounds for photodynamic therapy of cancer. J Med Chem (2008) 0.86
Nitrile-functionalized pyridinium ionic liquids: synthesis, characterization, and their application in carbon-carbon coupling reactions. J Am Chem Soc (2004) 0.86
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med (2014) 0.86
Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes. Dalton Trans (2013) 0.86
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. Dalton Trans (2010) 0.86
Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans (2007) 0.86
High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides. Inorg Chem (2008) 0.86
Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells. Inorg Chem (2011) 0.85
Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. Inorg Chem (2012) 0.85
Selective degradation of wood lignin over noble-metal catalysts in a two-step process. ChemSusChem (2008) 0.85
The dpsA gene of Streptomyces coelicolor: induction of expression from a single promoter in response to environmental stress or during development. PLoS One (2011) 0.85
Anticancer activity of opened arene ruthenium metalla-assemblies. Dalton Trans (2010) 0.85
Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds. J Inorg Biochem (2007) 0.85
Enhancing the stability of porphyrin dye-sensitized solar cells by manipulation of electrolyte additives. ChemSusChem (2014) 0.85
Functionalized pyrrolidine inhibitors of human type II alpha-mannosidases as anti-cancer agents: optimizing the fit to the active site. Bioorg Med Chem (2008) 0.85
Highly stable dye-sensitized solar cells based on novel 1,2,3-triazolium ionic liquids. ACS Appl Mater Interfaces (2014) 0.85
Hemocyanin with phenoloxidase activity in the chitin matrix of the crayfish gastrolith. J Exp Biol (2013) 0.85
Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication. Chem Biodivers (2008) 0.85
Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes. J Med Chem (2006) 0.84
Metal-based drugs that break the rules. Dalton Trans (2016) 0.84